Small peptide targeting ANP32A as a novel strategy for acute myeloid leukemia therapy

Clinic therapy of acute myeloid leukemia (AML) remains unsatisfactory that urges for development of novel strategies. Recent studies identified ANP32A as a novel biomarker of unfavorable outcome of leukemia, which promoted leukemogenesis by increasing H3 acetylation and the expression of lipid metab...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Manman, Guo, Hao, Zhang, Xuechun, Wang, Xiyang, Tao, Hu, Zhang, Tan, Peng, Min, Zhang, Min, Huang, Zan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529559/
https://www.ncbi.nlm.nih.gov/pubmed/34678588
http://dx.doi.org/10.1016/j.tranon.2021.101245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529559/
https://www.ncbi.nlm.nih.gov/pubmed/34678588
http://dx.doi.org/10.1016/j.tranon.2021.101245

Ejemplares similares